Search
Find a recruiting study
7,120 recruiting studies with US sites, from the official ClinicalTrials.gov registry (refreshed Oct 26, 2026). No sign-up needed.
Most recently updated studies · page 56 of 297
- RecruitingPhase 1
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
Novo Nordisk A/S
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18+
- Recruiting
Brain-Computer Interface Communication Device for People With ALS
Cognixion
- Location
- Santa Barbara, CA
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With…
Cabaletta Bio
- Location
- Redwood City, CA + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- La Jolla, CA + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 2
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
IRulya Therapeutics Inc.
- Location
- Tucson, AZ + 1 other US site
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2/Phase 3
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio
- Location
- Orange, CA + 29 other US sites
- Eligibility basics
- Ages 6–75
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Birmingham, AL + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Boehringer Ingelheim
- Location
- Salt Lake City, UT
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 16 other US sites
- Eligibility basics
- Ages 12–100
- Recruiting
Infant Formula in Infants and Children With Cow's Milk Allergy
Abbott Nutrition
- Location
- Phoenix, AZ + 7 other US sites
- Eligibility basics
- Ages 4 mo–12
- RecruitingPhase 2
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
Pfizer
- Location
- Orange, CA + 10 other US sites
- Eligibility basics
- Up to age 10 mo
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB Biopharma SRL
- Location
- Avondale, AZ + 61 other US sites
- Eligibility basics
- Ages 16+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Anniston, AL + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
Novartis Pharmaceuticals
- Location
- Sylmar, CA + 3 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Pfizer
- Location
- Huntsville, AL + 76 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 1
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Pfizer
- Location
- Los Angeles, CA + 2 other US sites
- Eligibility basics
- Ages 12–74 · Men only
- RecruitingPhase 1/Phase 2
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
BlueRock Therapeutics
- Location
- Los Angeles, CA + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Sanofi
- Location
- Indianapolis, IN + 2 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Sanofi
- Location
- Tucson, AZ + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Sanofi
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Ages 10–65
- Recruiting
Renal Pelvic Denervation Pilot Trial
Verve Medical, Inc
- Location
- Birmingham, AL + 7 other US sites
- Eligibility basics
- Ages 21–80
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb
- Location
- Scottsdale, AZ + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Irvine, CA + 18 other US sites
- Eligibility basics
- Ages 6–14
- Recruiting
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device…
Shockwave Medical, Inc.
- Location
- Little Rock, AR + 16 other US sites
- Eligibility basics
- Ages 18+
Data source: deploy-time snapshot of the ClinicalTrials.gov API. How we list studies